Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2002-06-07 Board/Management Inform…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG deutsch
Board/Management Information Classification · 98% confidence The document text announces a change in the company's supervisory board ('Aufsichtsratsmitglied'). Specifically, it states that Dr. Daniel Camus was appointed to the supervisory board during the recent Annual General Meeting (Hauptversammlung), and another member resigned. This directly relates to the composition of the company's governing body, which aligns with the definition for Board/Management Information (MANG). The document is short and focuses entirely on this personnel change.
2002-06-07 German
MorphoSys AG english
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated May 16, 2002, detailing an agreement where MorphoSys AG acquires anti-cancer antibodies from ProChon Biotech. This describes a significant corporate transaction involving the acquisition of assets/rights, which falls under Merger & Acquisition (M&A) activity or a major corporate transaction. Given the options, 'M&A Activity (Code: TAR)' is the most appropriate classification for an agreement involving the acquisition of development rights for therapeutic antibodies, even if it's not a full merger or takeover bid, as it represents a major strategic transaction. It is not an earnings release, capital change, or director dealing.
2002-05-16 English
MorphoSys AG english
Earnings Release Classification · 100% confidence The document is explicitly titled 'MorphoSys Reports First Quarter 2002 Results Ad-hoc-announcement' and provides key financial highlights (revenues, expenses, net loss, EBITDA, cash position) for the three months ended March 31, 2002. This structure—a brief announcement summarizing period results—fits the definition of an Earnings Release (ER). It is not a comprehensive Interim Report (IR) or a full Annual Report (10-K), but rather the initial release of the period's performance. Q1 2002
2002-05-13 English
MorphoSys AG deutsch
Earnings Release Classification · 100% confidence The document is titled 'MorphoSys veröffentlicht das Ergebnis des ersten Quartals 2002' (MorphoSys publishes the result of the first quarter 2002) and provides key financial highlights for the period ending March 31, 2002, including revenue, expenses, net loss, EBITDA, and cash position. This content structure—a brief announcement of key figures for a specific fiscal period shorter than a year—aligns perfectly with the definition of an Earnings Release (ER). It is not a comprehensive report (like 10-K or IR), nor is it a transcript or a presentation. Q1 2002
2002-05-13 German
MorphoSys AG english
Board/Management Information Classification · 99% confidence The document text is a corporate news announcement from MorphoSys AG, dated May 7, 2002. The content explicitly details the appointment of two key personnel: Dr. Claudia Gutjahr-Löser as Manager Corporate Communications and Dr. Alexander Oehmichen as General Counsel. This type of announcement, concerning changes in the company's senior management or board of directors, directly corresponds to the definition of 'Board/Management Information' (MANG). The document length is short (1940 chars), but it is the primary announcement itself, not an announcement *about* another report.
2002-05-07 English
MorphoSys AG deutsch
Board/Management Information Classification · 100% confidence The document is a short corporate news release dated May 7, 2002, announcing the appointment of two key personnel: Dr. Claudia Gutjahr-Löser as Manager Corporate Communications and Dr. Alexander Oehmichen as General Counsel. This type of announcement, detailing changes in senior management or the board of directors, directly corresponds to the definition for Board/Management Information (MANG). The document length is short (1974 chars), but it is the primary announcement itself, not a notice about another report, so the RPA/RNS rule does not apply here.
2002-05-07 German

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.